Anxiety in Parkinson's Disease

Current Clinical Neurology

Volumn 24, Issue , 2013, Pages 17-29

  Simuni, Tanya ^a   Fernandez, Hubert H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Agoraphobia; Anxiety disorders; Anxiety disorders in PD; Anxiety status inventory; Beck anxiety inventory; Hamilton anxiety rating scale; Hospital anxiety and depression scale; Spielberger state trait anxiety inventory; Zung self rating anxiety scale

Indexed keywords

4 AMINOBUTYRIC ACID; AMFEBUTAMONE; AMOXAPINE; BENZODIAZEPINE; BUSPIRONE; CITALOPRAM; DOPAMINE; FLUOXETINE; GLUTAMIC ACID; MIRTAZAPINE; NEUROPEPTIDE; NORADRENALIN; NORTRIPTYLINE; PAROXETINE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; SEROTONIN;

ANXIETY; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DEMENTIA; DEPRESSION; DISEASE SEVERITY; HUMAN; MOTOR PERFORMANCE; NEUROANATOMY; NEUROBIOLOGY; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; STRUCTURED QUESTIONNAIRE;

EID: 84899671402     PISSN: 15590585     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (103)

1. American Psychiatric Association. DSM-IV: diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Regier DA, Boyd JH, Burke Jr JD, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988; 45: 977-86.
3. Bland RC, Newman SC, Orn H. Prevalence of psychiatric disorders in the elderly in Edmonton. Acta Psychiatr Scand Suppl. 1988; 338: 57-63.
4. Negre-Pages L, Grandjean H, Lapeyre-Mestre M, et al. Anxious and depressive symptoms in Parkinson's disease: the French cross-sectional DoPaMiP study. Mov Disord. 2010; 25: 157-66.
5. Richard IH. Anxiety disorders in Parkinson's disease. Adv Neurol. 2005; 96: 42-55.
6. Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. 2009; 80: 928-30.
7. Lauterbach EC, Duvoisin RC. Anxiety disorders in familial parkinsonism. Am J Psychiatry. 1991; 148: 274.
8. Ringman JM, Diaz-Olavarrieta C, Rodriguez Y, Fairbanks L, Cummings JL. The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico. Neuropsychiatry Neuropsychol Behav Neurol. 2002; 15: 99-105.
9. Schiffer RB, Kurlan R, Rubin A, Boer S. Evidence for atypical depression in Parkinson's disease. Am J Psychiatry. 1988; 145: 1020-2.
10. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2002; 8: 193-7.
11. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D. "Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy. Acta Neurol Scand. 1993; 87: 14-8.
12. Walsh K, Bennett G. Parkinson's disease and anxiety. Postgrad Med J. 2001; 77: 89-93.
13. Pontone GM, Williams JR, Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord. 2009; 24: 1333-8.
14. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand. 2006; 113: 211-20.
15. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci. 2006; 248(1-2): 151-7.
16. Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. 2002; 17: 60-7.
17. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009; 24: 1641-9.
18. Leentjens AF, Dujardin K, Marsh L, et al. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2008; 23: 2015-25.
19. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988; 56: 893-7.
20. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67: 361-70.
21. Zung WW. A rating instrument for anxiety disorders. Psychosomatics. 1971; 12: 371-9.
22. Spielberger C, Gorsuch R, Edward L. STAI manual for the State-Trait Anxiety Inventory ("self-evaluation questionnaire"). Palo Alto, CA: Consulting Psychologists Press; 1970.
23. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959; 32: 50-5.
24. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44: 2308-14.
25. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord. 2009; 24: 2175-86.
26. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993; 34: 465-70.
27. Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry. 1990; 147: 217-20.
28. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000; 15: 669-77.
29. Stern MB, Siderowf A. Parkinson's at risk syndrome: can Parkinson's disease be predicted? Mov Disord. 2010; 25 Suppl 1: S89-93.
30. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976; 1: 292-6.
31. Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord. 1990; 5: 148-51.
32. Richard IH, Justus AW, Kurlan R. Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2001; 13: 35-41.
33. Lang AE, Quinn N, Brincat S, Marsden CD, Parkes JD. Pergolide in late-stage Parkinson disease. Ann Neurol. 1982; 12: 243-7.
34. Fleminger S. Left-sided Parkinson's disease is associated with greater anxiety and depression. Psychol Med. 1991; 21: 629-38.
35. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry. 1992; 149: 443-54.
36. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, pro file and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007; 78: 36-42.
37. Lauterbach EC. The locus ceruleus and anxiety disorders in demented and nondemented familial parkinsonism. Am J Psychiatry. 1993; 150: 994.
38. Iruela LM, Ibanez-Rojo V, Palanca I, Caballero L. Anxiety disorders and Parkinson's disease. Am J Psychiatry. 1992; 149: 719-20.
39. Weisskopf MG, Chen H, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord. 2002; 17: S146.
40. Arabia G, Grossardt BR, Geda YE, et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. Arch Gen Psychiatry. 2007; 64: 1385-92.
41. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986; 9: 357-81.
42. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004; 318: 121-34.
43. Mogenson GJ, Jones DL, Yim CY. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol. 1980; 14: 69-97.
44. Heimer L, Alheid GF, de Olmos JS, et al. The accumbens: beyond the core-shell dichotomy. J Neuropsychiatry Clin Neurosci. 1997; 9: 354-81.
45. Schiffer RB. Anxiety disorders in Parkinson's disease: insights into the neurobiology of neurosis. J Psychosom Res. 1999; 47: 505-8.
46. Jetty PV, Charney DS, Goddard AW. Neurobiology of generalized anxiety disorder. Psychiatr Clin North Am. 2001; 24: 75-97.
47. Pitchot W, Ansseau M, Gonzalez Moreno A, Hansenne M, von Frenckell R. Dopaminergic function in panic disorder: comparison with major and minor depression. Biol Psychiatry. 1992; 32: 1004-11.
48. Potts NL, Davidson JR. Social phobia: biological aspects and pharmacotherapy. Prog Neuropsychopharmacol Biol Psychiatry. 1992; 16: 635-46.
49. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Doseresponse relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a doubleblind, placebo-controlled study. Neurology. 1995; 45: 1757-60.
50. Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain. 2010; 133: 1111-27.
51. German DC, Manaye KF, White 3rd CL, et al. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol. 1992; 32: 667-76.
52. Patt S, Gerhard L. A Golgi study of human locus coeruleus in normal brains and in Parkinson's disease. Neuropathol Appl Neurobiol. 1993; 19: 519-23.
53. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005; 128: 1314-22.
54. Charney DS, Woods SW, Heninger GR. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res. 1989; 27: 173-82.
55. Cash R, Ruberg M, Raisman R, Agid Y. Adrenergic receptors in Parkinson's disease. Brain Res. 1984; 322: 269-75.
56. Richard IH, Szegethy E, Lichter D, Schiffer RB, Kurlan R. Parkinson's disease: a preliminary study of yohimbine challenge in patients with anxiety. Clin Neuropharmacol. 1999; 22: 172-5.
57. Raisman R, Cash R, Agid Y. Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology. 1986; 36: 556-60.
58. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain. 2008; 131: 120-31.
59. Drugan RC, Skolnick P, Paul SM, Crawley JN. A pretest procedure reliably predicts performance in two animal models of inescapable stress. Pharmacol Biochem Behav. 1989; 33: 649-54.
60. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin-and substance P-containing neurons in Parkinson's disease. Brain Res. 1990; 510: 104-7.
61. Rickels K, Case WG, Downing RW, Winokur A. Long-term diazepam therapy and clinical outcome. JAMA. 1983; 250: 767-71.
62. Agid Y, Cervera P, Hirsch E, et al. Biochemistry of Parkinson's disease 28 years later: a critical review. Mov Disord. 1989; 4 Suppl 1: S126-44.
63. Krystal JH, D'Souza DC, Petrakis IL, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry. 1999; 7: 125-43.
64. Trullas R, Jackson B, Skolnick P. Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors. Pharmacol Biochem Behav. 1989; 34: 313-6.
65. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010; 74: 924-31.
66. Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66: 996-1002.
67. Kulisevsky J, Pascual-Sedano B, Barbanoj M, Gironell A, Pagonabarraga J, Garcia-Sanchez C. Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: a doubleblind study. Mov Disord. 2007; 22: 62-7.
68. Rogers DC, Costall B, Domeney AM, et al. Anxiolytic pro file of ropinirole in the rat, mouse and common marmoset. Psychopharmacology (Berl). 2000; 151: 91-7.
69. Sethy VH, Ellerbrock BR, Wu H. U-95666E: a potential anti-parkinsonian drug with anxiolytic activity. Prog Neuropsychopharmacol Biol Psychiatry. 1997; 21: 873-83.
70. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000; 284: 1931-8.
71. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000; 342: 1484-91.
72. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000; 11: 58-65.
73. Lattanzi L, Dell'Osso L, Cassano P, et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord. 2002; 4: 307-14.
74. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009; 31: 89-98.
75. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010; 67: 58-63.
76. Connor KM, Davidson JR. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry. 1998; 44: 1286-94.
77. Menza M, Marin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci. 2004; 16: 315-9.
78. Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998; 19: 11-22.
79. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology. 1997; 48: 1070-7.
80. Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry. 1997; 9: 7-13.
81. Jimenez-Jimenez FJ, Tejeiro J, Martinez-Junquera G, Cabrera-Valdivia F, Alarcon J, Garcia-Albea E. Parkinsonism exacerbated by paroxetine. Neurology. 1994; 44: 2406.
82. Steur EN. Increase of Parkinson disability after fluoxetine medication. Neurology. 1993; 43: 211-3.
83. Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997; 25: 1211-4.
84. Stoudemire A. New antidepressant drugs and the treatment of depression in the medically ill patient. Psychiatr Clin North Am. 1996; 19: 495-514.
85. Artigas F, Nutt DJ, Shelton R. Mechanism of action of antidepressants. Psychopharmacol Bull. 2002; 36 Suppl 2: 123-32.
86. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology. 2009; 72: 886-92.
87. Vernier P, Pollak P, Groslambert R, Gavend M. Parkinsonian syndrome secondary to amoxapine. Presse Med. 1984; 13: 1007.
88. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology. 1984; 34: 1092-4.
89. Small GW. Recognizing and treating anxiety in the elderly. J Clin Psychiatry. 1997; 58 Suppl 3: 41-7. Discussion 48-50.
90. Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol. 1986; 9: 373-8.
91. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol. 1994; 17: 73-82.
92. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol. 1995; 10 Suppl 4: 25-35.
93. Pillon B, Ardouin C, Damier P, et al. Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology. 2000; 55: 411-8.
94. Saint-Cyr JA, Trepanier LL, Kumar R, Lozano AM, Lang AE. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain. 2000; 123(Pt 10): 2091-108.
95. Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol. 2008; 7: 605-14.
96. Temel Y, Kessels A, Tan S, Topdag A, Boon P, Visser-Vandewalle V. Behavioural changes after bilateral subthalamic stimulation in advanced Parkinson disease: a systematic review. Parkinsonism Relat Disord. 2006; 12: 265-72.
97. Voon V, Moro E, Saint-Cyr JA, Lozano AM, Lang AE. Psychiatric symptoms following surgery for Parkinson's disease with an emphasis on subthalamic stimulation. Adv Neurol. 2005; 96: 130-47.
98. Castelli L, Rizzi L, Zibetti M, Angrisano S, Lanotte M, Lopiano L. Neuropsychological changes 1-year after subthalamic DBS in PD patients: a prospective controlled study. Parkinsonism Relat Disord. 2010; 16: 115-8.
99. Lilleeng B, Dietrichs E. Unmasking psychiatric symptoms after STN deep brain stimulation in Parkinson's disease. Acta Neurol Scand Suppl. 2008; 188: 41-5.
100. Peron J, Vicente S, Leray E, et al. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease. Neuropsychologia. 2009; 47: 406-14.
101. Schupbach WM, Maltete D, Houeto JL, et al. Neurosurgery at an earlier stage of Parkinson dis ease: a randomized, controlled trial. Neurology. 2007; 68: 267-71.
102. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology. 2002; 58: 1019-24.
103. Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain. 2008; 131: 2720-8.